Clinilabs invites you to their event
About this event
Recent advances in the field of sleep medicine have led to an understanding of the underlying cause of narcolepsy, leading to a dramatic surge in the development of new investigational drugs. Several companies are now planning to head into clinic with studies of orexin receptor agonists as potential treatments for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and other related disorders.
Join Dr. Gary Zammit, President and CEO of Clinilabs Drug Development Corporation, as he discusses common pathways for clinical drug development in narcolepsy. Hear his discussion of the opportunities and challenges ahead as we race to bring forward new, safe, and effective treatments for narcolepsy.
Hosted by
Ms. Jeanine Falinski, VP of Strategy and Corporate Development, has more than 20 years of experience in the pharmaceutical industry. Jeanine graduated from Emerson College with a degree in New Media and Marketing, later on receiving her MBA in Pharmaceutical Management from Drexel University.
Monica Gow is a founder and executive director of Wake Up Narcolepsy, an international nonprofit organization based outside of Boston, MA. The organization's mission is to accelerate narcolepsy research, increase awareness, educate and support people with narcolepsy. Monica co-founded WUN in 2008 after her then 10 year old son was diagnosed with narcolepsy. Her passion is to improve the lives of people living with narcolepsy.
Gary Zammit is a neuroscientist and sleep specialist who founded Clinilabs Drug Development Corporation in 2001. He is widely recognized as a key opinion leader in the field of sleep medicine, and has been involved in the development of new drugs to treat sleep disorders such as narcolepsy, insomnia, excessive sleepiness, and circadian rhythm disorders.
We are a global, full-service contract research organization (CRO), the only one focused exclusively on central nervous system (CNS) drug development. We are dedicated to bringing new therapies to patients living with mental health, neurological and substance abuse disorders.
